Sector News

Another exec departs troubled Endo

October 21, 2016
Life sciences

Endo’s CEO exodus is continuing. Its CFO is following its CEO out the door–to work for another drugmaker, no less.

Thursday, the Dublin company announced that financial chief, Suketu Upadhyay, would be hitting the road to “assume a senior-level finance position at a global biopharmaceutical company.” Blaise Coleman, Endo’s SVP of Global Finance Operations, will step up in his stead while Endo searches for a permanent replacement.

It’s been a rocky financial year for Endo, which–much like Valeant, a company whose footsteps it’s seemingly been following in for years–slashed its Q2 guidance earlier this year, and the 40% share-price decline that ensued locked up the stock’s second-worse daily performance ever. It also cut 740 jobs. The company blamed new rivals on the market, greater-than-expected generics price erosion, regulatory delays and more for a revised revenue forecast that hit well below analyst expectations.

But new Endo skipper Paul Campanelli–the former Par chief who relieved Endo’s Rajiv De Silva late last month–was quick to point out that the company recently reaffirmed its third-quarter and full-year predictions, an attempt to reassure investors that more bad news wasn’t on the way.

What may be on the way for the troubled drugmaker, though? Divestments. Late in June, Reuters reported that Endo–like Valeant–was looking for asset sales that could help pay down its acquisition-fueled debt mountain. And Thursday, Campanelli noted that the specialty pharma would “complete a product-by-product assessment of our portfolio and further sharpen Endo’s strategy and operational focus.”

And analysts are already talking up potential takers. Earlier this week, RBC Capital Markets’ Randall Stanicky wrote in a note to investors that Endo’s pain business could make a good buy for California’s Depomed, which may scout for M&A now that it’s settled a proxy dispute with activist investor Starboard Value.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.